Health & Safety
Documents & Procedures:
- Procedure for alarm, firefighting and evacuation at IMDiK PAN in case of fire or other emergency.
- Regulations for the remuneration - allowance for work performed in harmful or uncomfortable conditions
- Eye-correcting glasses reimbursement
Occupational Health and Safety Instructions:
- Cleaning and maintenance activities using chemicals
- Safe handling of biocidal preparations
- Safe storage of cylinders of technical gases
- Operation of compressed medical oxygen cylinders
- Handling of material contaminated with harmful biological agents, including category 1 of activities of closed use of GMO
- General instructions for the use of hazardous chemical substances and preparations
- Instructions for exposure to substances, preparations with carcinogenic or mutagenic effects
Training materials:
Publication in "Leukemia"
The latest work of our researchers published in Leukemia
Publication: Leukemia – CAR-T cells directed to LILRB1
We are pleased to share our recent study on novel chimeric antigen receptor (CAR)-T cells targeting LILRB1, a promising new treatment strategy to improve immunotherapy for leukemia and potentially other hematologic malignancies. The research was carried out by the Polish-Norwegian consortium of the Medical University of Warsaw and Oslo University Hospital within the ALTERCAR project funded by the National Centre for Research and Development. It was led by Dr. Magdalena Winiarska and Dr. Małgorzata Firczuk from the Department of Immunology, MMRI. Other MMRI researchers participating in the project include Dr. Katsiaryna Marhelava, Msc. Marta Krawczyk, and Dr. Iwona Baranowska. The project also involved collaborations with institutions and hospitals in Poland and abroad, including the Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland; the Institute of Hematology and Transfusion Medicine, Warsaw, Poland; the Medical University of Silesia in Katowice, Poland; and the Josep Carreras Leukemia Research Institute, Barcelona, Spain.
In this study, we identified LILRB1 as a novel target on leukemia and lymphoma cells, and developed LILRB1-directed CAR-T cells. LILRB1 CAR-T cells offer a promising therapeutic opportunity for patients with B-cell malignancies who relapse after prior immunotherapies. In particular, this therapy may become a solution for B-cell acute lymphoblastic leukemia patients with CD19-negative relapses and lineage switching. The implementation of LILRB1 CAR-T cells may also extend beyond B-cell malignancies, offering hope for patients with monocytic leukemias and potentially providing a safer treatment option for acute myeloid leukemia, with reduced myelotoxicity compared to other currently tested CAR-T therapies.
Article in "Academia"
The latest issue of the Polish Academy of Sciences magazine "Academia" features article entitled "The Microbiote: freeloading passengers?" by Elżbieta Jagielska, PhD and Izabela Sabała, PhD, DSc from our Laboratory of Protein Engineering.
Enjoy reading!
Advancements of Microbiology 2025
MMRI PAS took patronage of the conference Advanvements of Microbiology 2025.
The team from our Protein Engineering Laboratory is involved in the organization of this event: the scientific committee of the conference includes Izabela Sabała, PhD and Elżbieta Jagielska, PhD who will also lead one of the sessions. Michal Zarod will give a lecture entitled: "YR_7, an innovative antimicrobial agent with high bactericidal activity against pathogenic Yersinia ruckeri infecting salmonid fish in aquaculture".
